MedPath

ShengJing Hospital of China Medical University (China Medical University No.2 Ho spital )

πŸ‡¨πŸ‡³China
Ownership
-
Employees
-
Market Cap
-
Website
http://www.sj-hospital.org

Clinical Trials

113

Active:6
Completed:26

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:4
Phase 2:16
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (67 trials with phase data)β€’ Click on a phase to view related trials

Not Applicable
34 (50.7%)
Phase 2
16 (23.9%)
Phase 4
9 (13.4%)
Phase 1
4 (6.0%)
Phase 3
3 (4.5%)
Early Phase 1
1 (1.5%)

Interventional AI-Human Collaboration for Liver Tumor Diagnosis

Not Applicable
Recruiting
Conditions
Hepatocellular Carcinoma (HCC)
Intrahepatic Cholangiocarcinoma (Icc)
Hepatic Metastasis
Hepatic Hemangioma
Cyst
Focal Nodular Hyperplasia
First Posted Date
2025-09-04
Last Posted Date
2025-09-22
Lead Sponsor
Shengjing Hospital
Target Recruit Count
10000
Registration Number
NCT07153783
Locations
πŸ‡¨πŸ‡³

Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

Near-Infrared Imaging of Motor Imagery Effects in Spinal Cord Injury

Not Applicable
Recruiting
Conditions
SCI - Spinal Cord Injury
Motor Imagery
Brain-Computer Interfaces
First Posted Date
2025-08-06
Last Posted Date
2025-08-06
Lead Sponsor
Shengjing Hospital
Target Recruit Count
36
Registration Number
NCT07106060
Locations
πŸ‡¨πŸ‡³

Rehabilitation Center of Shengjing Hospital, China Medical University, Shenyang, Liaoning, China

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Not Applicable
Not yet recruiting
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
Drug: JS004 in combination with toripalimab and chemotherapy
Drug: Toripalimab and chemotherapy
Drug: Chemotherapy
First Posted Date
2025-08-03
Last Posted Date
2025-08-03
Lead Sponsor
Shengjing Hospital
Target Recruit Count
125
Registration Number
NCT07101614

Effect of Threshold Pressure-Loaded RMT + tTBS on Respiratory Function in SCI Patients

Not Applicable
Recruiting
Conditions
Spinal Cord Injuries
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
Shengjing Hospital
Target Recruit Count
60
Registration Number
NCT07050069
Locations
πŸ‡¨πŸ‡³

Rehabilitation Center of Shengjing Hospital, China Medical University, Shenyang, Liaoning, China

Study on Dynamic Changes of Serum IGF-1 Post-Cerebral Hemorrhage and Its Prognostic Correlation

Not yet recruiting
Conditions
Insulin-Like Growth Factor I
First Posted Date
2025-06-29
Last Posted Date
2025-06-29
Lead Sponsor
Shengjing Hospital
Target Recruit Count
100
Registration Number
NCT07043504
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 23
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.